Navigation Links
Genova files patent for new prostate cancer treatment
Date:9/8/2009

NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

The peptide, called Prostaganin, is a 21-amino compound which is highly reactive to prostate cancer cells, and has the ability to specifically target them. In laboratory experiments, Prostaganin has demonstrated an ability to preferentially bind to and disrupt certain negatively charged components of the membranes of prostate cancer cells.

Prostaganin thus has tremendous potential as a superior new form of treating prostate cancer. Current treatment methods such as surgery, radiation and chemotherapy are outmoded, unsatisfactory, and have severe side effects. Prostaganin offers a positive alternative. The peptide, bio-engineered from naturally occurring compounds in the human body, can target and destroy cancerous cells, whilst leaving surrounding healthy tissues intact, and causing no undesirable side effects. Further development of this novel peptide could revolutionize the way people fight cancer.

The demand for new and better treatments for prostate cancer has never been higher. Prostate cancer presently accounts for 30% of all the major cancers in men. The Prostate Cancer Foundation states that prostate cancer is the cancer with the largest expected increase in the next decade, and that annual incidence of the cancer will rise to 300,000 cases in the U.S. alone by 2015.

"Prostaginin represents a significant milestone in GENova's business agenda to acquire patents for the most innovative new cancer treatments," says Aaron Whiteman, CEO of GENova, "But most importantly, it represents a new generation of cancer treatments that could save millions of lives, and treat prostate cancer in men with no side effects or adverse effects on quality of life. The implications are tremendous." Licensing to companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec could prove to be extremely lucrative in the short and long term. GENova works very hard on a daily basis to close agreements with big Biotechnology players in the industry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies. Visit GENova online at www.genovabio.comForward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova names Dr. John Savin as Vice President
2. GENova names Aaron Whiteman as CEO
3. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
4. InfoLogix Files Preliminary Proxy Statement in Connection with Special Meeting of Its Stockholders to Approve Recapitalization Plan
5. VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification
6. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
7. "Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing
8. AMDL Inc. Files Notification of Late Filing for Form 10-Q
9. Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches
10. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
11. Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... rising prescription opioid overdose deaths now claim the lives of 62 Americans each ... case filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of ... News website. , Rod has been at the forefront of Gardant since it was ... CEO, Rod has overseen the opening of more than 40 new senior living communities. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on ... Blvd, for an educational and exciting 2-day program. , An attendee at a ... before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... that over the last decade, student well-being has seriously declined. "When disenfranchised youth ... formal education, join the Islamic State to turn the historic multi-ethnic and multi-religious ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, and Omega ... Omega Station” is the creation of published author, Chris Jackson. Chris Jackson grew ... works in the Dallas Independent School District teaching English. He is heavily involved in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology: